Inovio Pharmaceuticals Inc.

Inovio Pharmaceuticals Inc. is taking immunotherapy to the next level in the fight against cancer and infectious diseases. They are the only immunotherapy company that has reported generating T cells in vivo in high quantity that are fully functional and whose killing capacity correlates with relevant clinical outcomes with a favorable safety profile. With an expanding portfolio of immune therapies, the company is advancing a growing preclinical and clinical stage product pipeline. Partners and collaborators include MedImmune, Roche, The Wistar Institute, University of Pennsylvania, DARPA, GeneOne Life Science, Plumbline Life Sciences, Drexel University, NIH, HIV Vaccines Trial Network, National Cancer Institute, U.S. Military HIV Research Program, and University of Manitoba.

Expert Comments:

Zacks Equity Research (4/12/17)
"Inovio Pharmaceuticals, Inc. recently reported positive preliminary results from the expanded stage of its phase I study, EBOV-001. The study was conducted to evaluate the company's Ebola DNA vaccine, INO-4212. The company has enrolled an additional 125 patients in the study. . .the EBOV-001 study demonstrated robust immune responses with favorable safety profile in expanded clinical study. It showed that 95% of the subjects generated an Ebola-specific antibody immune response with the mean antibody titer superior to those reported from viral vector-based Ebola vaccines. . .the company was awarded a $45 million grant by the Defense Advanced Research Projects Agency in 2015 to lead a collaborative team for the development of multiple treatment and prevention approaches for Ebola."

Ram Selvaraju, H.C. Wainwright & Co. (3/16/17)
"Inovio Pharmaceuticals Inc. is generating data with the Cellectra® 5PSP delivery device in order to satisfy the FDA's requirement regarding the shelf-life of its disposable components, so that the clinical hold on the Phase 3 pivotal study of VGX-3100 for the treatment of HPV-16/18- related high grade cervical dysplasia could be lifted. . .we note that VGX-3100 would be the first candidate within the company's extensive pipeline to enter a pivotal study. In the wake of this update, we reiterate our Buy rating and $13 price target."

Jason McCarthy, Maxim Group (3/16/17)
"Inovio Pharmaceuticals Inc.'s VGX-3100 study should start in 1H17, multiple catalysts ahead in other programs. . .with a combination of moving closer to the pivotal study in cervical dysplasia and multiple earlier stage programs moving forward with more significant data points coming throughout 2017, we are upgrading to a Buy rating."

Charles Duncan, Piper Jaffray & Co. (3/16/17)
"Inovio Pharmaceuticals Inc. reported 4Q16 revenues of $8.5M, R&D of $23.9M, and SG&A of $7M. Revenues and R&D were slightly above our projections. . .the biotech indices demonstrated positive growth in the last month, perhaps representing a relief rally. Strong fundamental stories can clearly still deliver value creation despite a noisy political environment and drug pricing pressures."

Zacks Equity Research (3/6/17)
"Inovio Pharmaceuticals Inc.'s VGX-3100 is the most advanced candidate in the company’s pipeline. . .it now expects the program to be delayed until the first half of 2017, pending resolution of the FDA’s requests. . .Apart from VGX-3100, Inovio has several other candidates in its pipeline in early- to mid-stage development. . .the company is working on the development of Ebola, Zika and Middle East respiratory syndrome virus vaccines. . .Investor focus should remain on pipeline updates as many such events are lined up along with the company’s plans related to the development of its Ebola and Zika vaccines."

Ram Selvaraju, H.C. Wainwright & Co. (2/24/17)
"Preliminary data show immune responses in 100% of Zika-vaccinated and 98% of MERS-vaccinated human subjects. . .both vaccines have demonstrated a favorable safety profile without significant adverse events. . .both Phase 1 trials are fully enrolled, and we expect the company to report additional data later this year for the prevention of MERS and Zika infections, which have no approved vaccines or treatments. . . Earlier this month, Inovio entered into a license agreement that provides ApolloBio Corporation with the exclusive right to develop and commercialize VGX-3100 in Greater China."

Inovio's Zika vaccine has demonstrated robust antigen-specific antibody responses in a Phase 1 study with 40 volunteers.
read more >

More Expert Comments

Experts Following This Company

Larry Biegelsen – Wells Fargo Securities
Jim Birchenough – BMO Capital Markets
Charles Duncan, Managing Director, Senior Biotechnology Analyst – Piper Jaffray & Co.
Nick Hodge, Founder and president of the Outsider Club – Outsider Club
Jason Kolbert, Senior Analyst – Maxim Group
Jason McCarthy, Analyst – Maxim Group
Ram Selvaraju, Managing Director; Head of Healthcare Equity Research – Rodman & Renshaw

The information provided above is from analysts, newsletters, the company and other contributors.

Inovio Pharmaceuticals Inc. is a sponsor of Streetwise Reports. The company's sponsorship fees pay for Streetwise Reports to create and update this "Investor Summary Page," to which links are placed on Streetwise Reports' websites and newsletters. Streetwise Reports does not accept stock for the payment of fees. See disclaimer for more details.

The company description, investing highlights and catalyst calendar on this page were prepared by the company. The Expert Comments and Experts Following This Company sections of this page are compiled by Streetwise Reports. There may be other information about the company that is not placed on this page. Streetwise Reports does not guarantee the accuracy or thoroughness of the information contained on this page.

The Expert Opinions above are excerpted from third-party sources not affiliated with or controlled by Streetwise Reports. The statements or opinions expressed in the Expert Opinions above are those of the authors indicated, and Streetwise Reports has not verified the accuracy of material excerpted here.

Streetwise Reports does not provide investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security.Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.

Readers should conduct their own research for all information publicly available concerning the company.